ArticleClinics and research in hepatology and gastroenterology2021
Is targeting autophagy a promising lead to unveil the cloak of invisibility in pancreatic cancer?
Article in Clinics and research in hepatology and gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma PDAC is considered as one of the less immunogenic solid tumor types. Pancreatic tumors are also known to present a high autophagy flux which supports tumor progression. Autophagy was recently described as a tumor-intrinsic immune escape process during tumor development by sequestration of Major Histocompatibility Complex class I (MHC-I) inside the PDAC cells. We comment this discovery and discuss the implications on how to limit immune escape in patients and how to improve immunotherapy efficiency. Currently, pancreatic adenocarcinoma is the most frequent pancreatic cancer with a poor prognosis, an important lethality, and a 5-year overall survival less than 5%. The development of some therapeutic solutions like targeted therapies are promising [1]. However, it is still important to understand this morbid pathology to improve the treatment, because PDAC is predicted to be the second leading cause of death in Western countries [2].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.